AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune ...

On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a flexible-dose (5mg to 15mg, once daily) monotherapy in early ...

AT&T is aiming to reward shareholders handsomely and already has a fat dividend yield. AbbVie has lots of drugs in development, some of which might become blockbusters. Johnson & Johnson has ...

AbbVie ABBV announced positive top-line results from the pivotal phase III TEMPO-2 study, which evaluated its recently acquired investigational drug tavapadon in adults with early Parkinson’s ...

According to a press release, AbbVie, the acquiring company, said the move aims to accelerate the development of Nimble's innovative oral therapies designed to treat psoriasis and inflammatory ...

AbbVie announced the completion of its acquisition of Aliada Therapeutics. 1 As a result, Aliada’s lead investigational asset, ALIA-1758, is an Alzheimer’s treatment that’s in Phase 1 trials and will ...

The Food and Drug Administration cited AbbVie for making misleading claims about a migraine pill in TV ads featuring tennis ...

INR:7252. picvook tv Pfizer and Eli Lilly are ahead of AbbVie and are closely following the new battlefield of JAK inhibitors. Is this the place? New tumor immunothera ...

Texas native Dana Kendall will lead the global biopharmaceutical company AbbVie’s Irish division as its general manager, the company said in an announcement today (16 December). Based at AbbVie ...